Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
Vor Bio (Nasdaq: VOR) announced that clinical data from the initial patient treated in its VBP101 study has been accepted for presentation at the 2023 Tandem Meetings from February 15-19 in Orlando, Florida. This Phase 1/2a trial is focused on trem-cel (formerly VOR33) for patients with acute myeloid leukemia (AML). The late-breaking poster presentation, titled "Initial First-in-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT)," will showcase important findings including tolerability of Gemtuzumab Ozogamicin without cytopenias.
- Clinical data accepted for presentation at a significant medical conference.
- The study highlights normal engraftment and tolerability of therapies without cytopenias.
- None.
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML) has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19 in Orlando, Florida.
Details about the presentation are as follows:
Title: Initial First-in-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias
Abstract Number: LBA14
Poster Display Hours: Thursday, February 16 from 12:00 PM to 8:00 PM ET; Friday, February 17 from 7:30 AM to 7:00 PM ET; and Saturday, February 18 from 7:30 AM to 3:00 PM ET.
Poster Presentation: “Tandem Meetings Poster Reception: Meet the Authors” on Thursday, February 16 from 5:45 PM to 6:45 PM ET.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
What is the objective of the VBP101 study by Vor Bio?
When will the VBP101 study results be presented?
What are the key findings from the VBP101 study?
How does Vor Bio's research impact the treatment of acute myeloid leukemia?
